Alliance Wealth Advisors LLC UT Acquires Shares of 3,816 DexCom, Inc. (NASDAQ:DXCM)

Alliance Wealth Advisors LLC UT bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 3,816 shares of the medical device company’s stock, valued at approximately $297,000.

Other hedge funds also recently modified their holdings of the company. Geode Capital Management LLC grew its stake in DexCom by 2.2% during the third quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company’s stock worth $664,056,000 after buying an additional 214,136 shares in the last quarter. Jennison Associates LLC lifted its holdings in shares of DexCom by 10.3% during the 4th quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company’s stock worth $594,455,000 after acquiring an additional 710,858 shares during the period. Groupama Asset Managment boosted its position in shares of DexCom by 1.1% during the 3rd quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company’s stock worth $1,912,000 after acquiring an additional 31,358 shares in the last quarter. Westfield Capital Management Co. LP boosted its position in shares of DexCom by 44.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock worth $190,532,000 after acquiring an additional 876,739 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in DexCom by 11.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,734,155 shares of the medical device company’s stock valued at $183,298,000 after purchasing an additional 288,381 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

Shares of DXCM opened at $87.46 on Wednesday. The business has a 50-day moving average of $80.95 and a 200-day moving average of $75.77. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The company has a market capitalization of $34.16 billion, a price-to-earnings ratio of 52.37, a price-to-earnings-growth ratio of 2.23 and a beta of 1.14. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the sale, the executive vice president now directly owns 83,526 shares in the company, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the transaction, the chief executive officer now directly owns 319,037 shares in the company, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 42,342 shares of company stock valued at $3,628,069. 0.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Raymond James reduced their target price on DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a report on Friday, October 25th. Leerink Partners reduced their price objective on DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Wells Fargo & Company lifted their target price on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Finally, Oppenheimer decreased their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $98.41.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.